Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la

Multiple Sclerosis

Volumn 4, Issue 6, 1998, Pages 487-489

  Mohr, David C ^a   Likosky, William ^b   Boudewyn, Arne C ^a   Marietta, Peter ^a   Divyer, Pat ^a   Van Der Wende, Judy ^a   Goodkin, Donald E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kaiser Permancnic Med Care Program   (United States)

Author keywords

Compliance; Interferon; Multiple sclerosis; Side effects

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; CHILL; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYALGIA; PARESTHESIA; PATIENT COMPLIANCE; SKIN TINGLING;

EID: 0032438047     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859800400605     Document Type: Article

References (6)

1. Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285-294.
2. Kurtzke JR (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 33: 1444-1452.
3. Mohr DC et al. (1996) Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment. Multiple Schlerosis 2: 222-226.
4. Neilley LK, Goodin DS, Goodkin DE, Hauser SL (1996) Side effect profile of interferon beta-1b in MS: Results of an open label trial. Neurol 46: 552-554.
5. Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis. Ann Neurol 13: 227-231.
6. Sharrack B, Hughes RAG, Soudain S. (1996) Guy's Neurological Disability Scale. Journal of Neurology 243: P171.